Literature DB >> 18637831

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

Chaichon Locharernkul1, Jakrin Loplumlert, Chusak Limotai, Wiwat Korkij, Tayard Desudchit, Siraprapa Tongkobpetch, Oratai Kangwanshiratada, Nattiya Hirankarn, Kanya Suphapeetiporn, Vorasuk Shotelersuk.   

Abstract

PURPOSE: Previous studies found a strong association between HLA-B*1502 and carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) in Han Chinese, but not in Caucasian populations. Even in Han Chinese, the HLA-B*1502 was not associated with CBZ-induced maculopapular eruptions (MPE). This study seeks to identify whether HLA-B*1502 is associated with CBZ- or phenytoin (PHT)-induced SJS or MPE in a Thai population.
METHODS: Eighty-one Thai epileptic patients between 1994 and 2007 from the Chulalongkorn Comprehensive Epilepsy Program were recruited. Thirty-one subjects had antiepileptic drug (AED)-induced SJS or MPE (6 CBZ-SJS, 4 PHT-SJS, 9 CBZ-MPE, 12 PHT-MPE), and 50 were AED-tolerant controls.
RESULTS: For the first time, a strong association between HLA-B*1502 and PHT-induced SJS was found (p = 0.005). A strong association was also found between the HLA-B*1502 and CBZ-induced SJS (p = 0.0005), making Thai the first non-Chinese population demonstrating such an association. Some patients, who were HLA-B*1502 and suffered from CBZ-induced SJS, could be tolerant to PHT and vice versa. This suggests that HLA-B*1502 may be a common attribute required for a Thai patient to develop SJS from these two AEDs; other different elements, however, are also needed for each AED. In addition, no association between HLA-B alleles and CBZ- or PHT-induced MPE was found.
CONCLUSIONS: CBZ- and PHT-induced SJS, but not MPE, is associated with HLA-B*1502 allele in Thai population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637831     DOI: 10.1111/j.1528-1167.2008.01719.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  104 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  Pharmacogenetics and pharmacovigilance.

Authors:  Robert H Howland
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

Review 5.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

6.  Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.

Authors:  Robert L Davis; Mia A Gallagher; Maryam M Asgari; Melody J Eide; David J Margolis; Eric Macy; James K Burmester; Nandini Selvam; Joseph A Boscarino; Lee F Cromwell; Heather S Feigelson; Jennifer L Kuntz; Pamala A Pawloski; Robert B Penfold; Marsha A Raebel; Gayathri Sridhar; Ann Wu; Lois A La Grenade; Michael A Pacanowski; Simone P Pinheiro
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-24       Impact factor: 2.890

7.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.

Authors:  Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing
Journal:  Pharmacogenomics J       Date:  2016-08-16       Impact factor: 3.550

8.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

9.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

10.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.